Background
Human papillomaviruses (HPV) are a large family of epitheliotropic DNA tumor viruses [
1]. Approximately 80% of sexually active women are infected with at least one HPV subtype at some point in their lifetimes [
2]. Continuous infection with a high-risk HPV subtype is the main cause of cervical cancer [
3]. The HPV high-risk subtypes include HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. Among them, HPV 16 and 18 are highly associated with cervical cancer, and cause about 75% of cervical cancers worldwide [
4]. Cervical cancer has become a global public health problem. It is the fourth most common cancer in women. In 2020, an estimated 604,000 women worldwide were diagnosed with cervical cancer, and an estimated 342,000 women died. In China, 110,000 new cases of cervical cancer and 59,000 deaths were reported, therefore having the second-largest burden of cervical cancer in the world [
5]. Cervical cancer in China accounts for 18% of the worldwide cervical cancer incidence and 17% of cervical cancer deaths.
As the only cancer that has clear causes, and can be prevented and treated, it is expected to be fully eradicated. Therefore, promoting cervical cancer prevention is of great importance. Vaccination is an effective measure against HPV infection and to reduce cervical cancer incidence. Three prophylactic HPV vaccines are currently available worldwide, including the bivalent, quadrivalent, and 9-valent HPV vaccines [
6]. The World Health Organization (WHO) recommends using HPV vaccination as part of routine vaccination in all countries [
7]. HPV vaccines are currently used in 129 countries worldwide to prevent HPV-related diseases [
8] and have been introduced into the national immunization plans (NIP) of 74 countries [
9]. However, the HPV vaccination is not included in China’s NIP.
China has approved HPV vaccines since 2016 [
10], including the Cervarix® (GlaxoSmithKline Inc.), Cecolin® (Wantai BioPharm), and Gardasil® and Gardasil® 9 (Merck & Co., Inc.) vaccines. It has a large population and unbalanced economic development among regions. The payment methods for obtaining HPV vaccination services are different among various provinces. Currently, there are three main payment methods for HPV vaccines in China: 1) residents are vaccinated against HPV at their own expense, 2) target populations get free HPV vaccination, such as in Ordos, Inner Mongolia, and Xiamen [
11,
12], and 3) medical insurance does a co-payment with residents for the vaccine. However, in Guizhou Province, HPV vaccination is paid through the balance of the employee’s personal medical insurance account [
13]. The local government-led free HPV vaccination program is rare in China. Most provinces still need residents to get vaccinated at their own expense, and residents experience a heavy burden of paying for the HPV vaccine. In 2019, China’s Vaccine Management Law authorized provincial governments to increase the types of vaccines available for immunization programs in accordance with the needs of disease prevention and control in their administrative regions [
14]. However, China still lacks the economic evidence for HPV vaccine cost-effectiveness at the national and provincial levels. To provide information that could affect policy-making decisions to expand the use of HPV vaccines, we evaluated the economics of all valent HPV vaccines available in the Chinese market at the national and provincial levels.
Methods
Cost-effectiveness analysis was used to assess the economics of HPV vaccination at a national level and in 31 provinces in Mainland China. From the perspective of the health system, we compared the final cost and health effects of the two strategies of vaccinating and not vaccinating HPV vaccine for women of the target age. The HPV vaccines available in the Chinese market include the domestic bivalent, imported bivalent, imported quadrivalent, and imported 9-valent HPV vaccines. Lifetime effects after vaccination were estimated using the Papillomavirus Rapid Interface for Modeling and Economics (PRIME) model. The results of the economic evaluation were expressed by incremental cost-effectiveness ratios (ICER), and ICER indicators that were constructed based on the disability-adjusted life years (DALYs) were reported. The evaluation assumed that the target population had not been infected with HPV prior to vaccination. Stata15.0 was used to draw a map of China to show the cost-effectiveness results. Sensitivity analysis was conducted to test the impact of six parameters, including target age, discounted rate, vaccine efficacy, procurement, transportation and management cost, and cervical cancer treatment cost, on the robustness of the model results; the results are shown in a tornado diagram. The cost parameters used in the model have been adjusted to 2019 according to the average exchange rate of the RMB against the US dollar and the consumer price index [
15]. To eliminate the effect of the time value of money, costs were discounted at a rate of 3%, as recommended by the WHO Guidelines on Health Economics [
16]. This study is reported as per the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) guideline (Additional file
1: Table S1) [
17].
PRIME model
The PRIME model was used to conduct an economic evaluation of different HPV vaccines in different provinces and cities in China [
18]. The PRIME model is a static proportional outcome model, developed by Jit et al. with support from the WHO [
19]. The model aims to aid in the health economic assessment of HPV vaccination for decision-makers and medical workers at all levels. The model considered the association between HPV infection and cervical cancer lesions. Three vaccines are protective against various high-risk HPV subtypes. The bivalent and quadrivalent HPV vaccines are protective against two high-risk HPV subtypes. The 9-valent HPV vaccine is protective against seven high-risk HPV subtypes, which include HPV 16, 18, 31, 33, 45, 52, and 58. We set model parameters based on heterogeneous data from various regions. Table
1 lists the model parameters and their sources.
Table 1
PRIME model parameters and data sources
Birth cohort size (female) | Additional file | CPSY |
Cohort size at vaccination age (female) | Additional file | CPSY |
Target age group | 9/16 | |
Vaccine efficacy vs HPV 16/18 | 100% | |
Vaccine efficacy vs HPV 16/18/31/33/45/52/58 | 100% | |
Coverage (all doses) | 80% | |
Vaccine price per FIG | Additional file | CPP |
Vaccine delivery cost per FIG | Additional file | CPP |
Total vaccine cost per FIG | Additional file | CPP |
Cancer treatment cost (per episode, over lifetime) | US$7547 | |
DALYs for cancer diagnosis | 0.08 | |
DALYs for non-terminal cancer sequelae (per year) | 0.11 | |
DALYs for terminal cancer | 0.78 | |
Discount rate | 3% | |
Proportion of cervical cancer cases that are due to HPV 16/18 | 69.1% | |
Proportion of cervical cancer cases that are due to HPV 16/18/31/33/45/52/58 | 92% | |
Discounted GDP per capita | Additional file | CPSY |
Demographic and regional economic data
The 2019 national and provincial statistics included the number of women born in the cohort and the number of women of target vaccination age in the region. The target age was set according to the age at which HPV vaccination was approved in Mainland China [
20]. The target age of vaccination for the bivalent and quadrivalent HPV vaccines was set at 9 years and that for the 9-valent HPV vaccine was set at 16 years.
Regional per capita gross domestic product (GDP) refers to the value of all final products and services produced less the value of products and services used for immediate consumption by all residential units in a region over a period. Since the publication of the Statistical Yearbook data lags behind by 1 year, the demographic and regional economic data used were from the 2020 Statistical Yearbook of each province. Cohort size at vaccination age (female) was calculated from the national population age structure. Data and calculation formulas are shown in Additional file
2: Tables S2–S4 and Additional file
3: Table S5.
Disease burden data
The disease burden data included epidemiological and economic burden data. Data on the proportion and incidence of and mortality due to cervical cancer caused by different HPV subtypes are obtained from the International Agency for Research on Cancer (IARC) HPV Information Center; data on the DALYs lost due to cervical cancer or death are obtained from the Global Burden of Disease research [
21]. The cost of treatment for cervical cancer per capita was based on the cost of treatment for cervical cancer per patient from the time of diagnosis until death [
22]. Disease burden data in the model are those for the national level.
Vaccine efficacy and coverage rates
The vaccine efficacy was based on the proportion of the reduction in the risk of developing cervical cancer associated with the bivalent, quadrivalent and 9-valent HPV vaccines, which we set at 100% [
23,
24]. The rollout of HPV vaccination in China is in the initial stages, with coverage data at the national and provincial levels not available. Therefore, the coverage of HPV vaccination was estimated to be 80% [
25,
26].
Vaccination costs
Vaccination costs included per capita vaccine procurement, transportation and management, and service costs. Details of the data are recorded in Additional file
4: Tables S6–S8. The per capita procurement cost was based on the transaction price of the centralized purchase of HPV vaccines by various provinces and cities in China. The per capita vaccine transportation and management, and service costs were based on the transportation fee and service fee of all class II or non-immunization planning vaccines published by various provinces and cities in China. Class II and non-immunization planning vaccines refer to the vaccines received by residents voluntarily, and at their own expense [
27].
Economic evaluation indicators
Costs included the direct and discounted costs, and the incremental costs incurred between receiving HPV vaccines and not receiving them. These costs included vaccination, saved treatment, and net costs. The effect of HPV vaccination was based on the number of cervical cancer cases and deaths averted before and after vaccination. Life-years saved (DALYs averted) were based on the number of life-year (DALY) losses eventually averted due to cervical cancer cases averted by vaccinating a single age cohort in 2019. We also calculated the incremental cost of preventing one case of cervical cancer after HPV vaccination, preventing one death, and of saving the unit DALY. Cost effect is the ratio of the increased cost of saving a unit DALY (cost-effectiveness ratio, CER) and the incremental CER obtained compared to existing standard strategies. ICER of each province was compared with GDP per capita of each region; ICER < 1 times GDP per capita is very cost-effective, 1 < ICER< 3 times per capita GDP is cost-effective, and ICER> 3 times GDP is not cost-effective at all. The calculation formula of the cost and effect index is in Additional file
5.
Sensitivity analysis
Univariate sensitivity analysis was performed on the target age, vaccine efficacy, procurement cost, transportation and management cost, discount rate, and cervical cancer treatment cost in the model at the national level. The values of three cost-related parameters, including vaccine procurement, transportation and management costs, and cervical cancer treatment cost were adjusted by ±20%; vaccine efficacy was adjusted by − 10% and − 20%; discount rate was adjusted by ±2%; and target age for vaccination was adjusted to 13 and 26 years. We compared the changes in results caused by index changes when the target population was vaccinated with an HPV vaccine, analyzed the robustness of the model, and found the index that had the greatest impact on the results. The uncertainties of the model are summarized by a tornado diagram.
Discussion
This study evaluated the cost-effectiveness of HPV vaccination at the national and provincial levels in China compared with no HPV vaccination. Compared with not vaccinating with the HPV vaccine, vaccinating with the HPV vaccine can reduce the incidence of cervical cancer cases in women of all ages. When HPV vaccine coverage reached 80%, for the target population in 2019, introducing bivalent, quadrivalent or 9-valent HPV vaccines into the immunization program could have averted more than 12,545–28,140 cervical cancer cases and approximately 5109–11,459 deaths. Once the HPV vaccine is included in the immunization program, 80% vaccine coverage can be expected. In 2020, Erdos, China, implemented a program for free HPV vaccination for girls aged 13–18 years, and the vaccination rate of the target population reached 85% [
28]. The incremental cost of using the domestic bivalent, imported bivalent, imported quadrivalent, and imported 9-valent HPV vaccines for each DALY saved is US$ 7213, US$ 13,074, US$ 18,165, and US$ 16,939, respectively. With 3 times GDP per capita as the threshold, HPV vaccination is cost-effective nationwide. This result is consistent with the research results of HPV vaccination in Vietnam, Australia, South Africa, and other countries [
29‐
31].
With the 3 times per capita GDP as the threshold, the usage of the domestic and imported bivalent HPV vaccines in 31 provinces is cost-effective. Among them, the domestic bivalent vaccine is very cost-effective in 22 of the 31 provinces due to its price advantage. The imported bivalent HPV vaccine is very cost-effective in six economically developed regions (per capita GDP in 2019 > US$ 13,655). Except for Heilongjiang and Gansu, usage of the imported quadrivalent and 9-valent HPV vaccines in other provinces was cost-effective. In the deterministic sensitivity analysis, when the most model parameters were changed, HPV vaccination was still cost-effective.
The net cost of the 9-valent HPV vaccine was higher. However, the 9-valent HPV vaccine protects against more HPV subtypes, prevents more morbidity, and saves more treatment costs than the other vaccines. The reduction in the cost of the 9-valent HPV vaccine can further reduce its net cost. For cervical cancer, bivalent and quadrivalent HPV vaccines have the same protective effect. Currently, the net cost depends on the vaccine price. The bivalent HPV vaccines, especially the domestic bivalent HPV vaccine, have the greatest price advantage and the lowest net cost.
There are provincial differences in the economics of HPV vaccination. The increased cost is either completely worth it, or it is accepted that it is affected by the ICER value and threshold. The ICER values for the domestic bivalent HPV vaccine in Gansu and Beijing were 7138 (US$/DALY gained) and 7254 (US$/DALY gained), respectively; the per capita GDP was US$ 4784 and US$ 23,811, respectively. In Beijing, even if the 9-valent HPV vaccine was used at its highest price, its ICER value was still less than double the per capita GDP. In Gansu, even if the domestically made bivalent HPV vaccine was used at its lowest price, its ICER value was only less than 3 times the per capita GDP. The level of economic development in each province will affect its ability to pay for HPV vaccines. Including the HPV vaccine in the scope of medical insurance payments or state subsidies can increase the availability of HPV vaccines in economically disadvantaged areas.
This study had some limitations. First, our study only considered the protective effect of HPV vaccines on cervical cancer and did not consider the protective effect of HPV vaccines on genital warts, oral cancer, and other diseases, which may have caused the ICER to be overestimated. Second, we assumed that the target age population had not been infected with HPV when entering the model, but there may have been people who were infected with HPV. Third, the impact of cervical cancer screening and HPV transmission on the incidence of cervical cancer was not considered, and the herd immune response was also not considered. Fourth, the vaccine dropout rate, due to side effects after vaccination, was not considered.
Conclusions
The HPV vaccine being included in the immunization program can reduce the burden of cervical cancer. As a country with a large population, to help accelerate the elimination of cervical cancer, China should include the HPV vaccine in its immunization program as soon as possible. From a provincial perspective, Guangdong, Shandong, Henan, Sichuan, and Jiangsu have benefited from the preventable cervical cancer incidence and avoidable cervical cancer deaths after HPV vaccination, and consideration should be given to including the HPV vaccine in their immunization programs as soon as possible. In various provinces, there is a large gap in the ability to pay for HPV vaccines. To improve the accessibility of HPV vaccines, more attention should be given to economically disadvantaged areas.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.